CA2334702A1 - Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol - Google Patents
Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol Download PDFInfo
- Publication number
- CA2334702A1 CA2334702A1 CA002334702A CA2334702A CA2334702A1 CA 2334702 A1 CA2334702 A1 CA 2334702A1 CA 002334702 A CA002334702 A CA 002334702A CA 2334702 A CA2334702 A CA 2334702A CA 2334702 A1 CA2334702 A1 CA 2334702A1
- Authority
- CA
- Canada
- Prior art keywords
- beta
- androst
- ene
- diol
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Androst-5-ene-3.beta.,17.beta.-diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9628698A | 1998-06-11 | 1998-06-11 | |
US09/096,286 | 1998-06-11 | ||
PCT/CA1999/000537 WO1999063973A2 (en) | 1998-06-11 | 1999-06-10 | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2334702A1 true CA2334702A1 (en) | 1999-12-16 |
CA2334702C CA2334702C (en) | 2005-10-18 |
Family
ID=22256669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002334702A Expired - Fee Related CA2334702C (en) | 1998-06-11 | 1999-06-10 | Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol |
Country Status (23)
Country | Link |
---|---|
US (12) | US6432940B1 (en) |
EP (2) | EP1083904A2 (en) |
JP (1) | JP2002517432A (en) |
KR (3) | KR100679735B1 (en) |
CN (3) | CN1879630A (en) |
AR (1) | AR018660A1 (en) |
AU (1) | AU4127499A (en) |
BR (1) | BR9911115A (en) |
CA (1) | CA2334702C (en) |
HK (2) | HK1037329A1 (en) |
HU (1) | HUP0102483A3 (en) |
ID (1) | ID27922A (en) |
IL (2) | IL140225A0 (en) |
MX (1) | MXPA00012304A (en) |
MY (1) | MY131522A (en) |
NO (1) | NO20006286L (en) |
NZ (1) | NZ536787A (en) |
PL (1) | PL345955A1 (en) |
RU (1) | RU2221569C2 (en) |
TR (2) | TR200102867T2 (en) |
TW (2) | TWI283579B (en) |
WO (1) | WO1999063973A2 (en) |
ZA (1) | ZA200007299B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CN1879630A (en) * | 1998-06-11 | 2006-12-20 | 内部研究股份有限公司 | Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol |
US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
CA2376797C (en) | 1999-06-11 | 2011-03-22 | Watson Pharmaceuticals, Inc. | Administration of non oral androgenic steroids to women |
WO2001001969A2 (en) | 1999-07-06 | 2001-01-11 | Endorecherche, Inc. | Methods of treating and/or suppressing weight gain |
CA2670236C (en) * | 1999-09-30 | 2012-06-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
AU7896100A (en) * | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
FR2803750B1 (en) * | 2000-01-17 | 2004-04-02 | Assist Publ Hopitaux De Paris | ORAL USE OF DEHYDROEPIANDROSTERONE, ITS BIOLOGICAL PRECURSORS AND ITS METABOLIC DERIVATIVES AS AN ANTI-ATROPHYANT |
US7241753B2 (en) | 2000-02-25 | 2007-07-10 | Loria Roger M | Method of treatment of prostate cancer |
DE10039199A1 (en) * | 2000-08-10 | 2002-02-21 | Schering Ag | Combination preparations from an ERß selective estrogen and a SERM or antiestrogen |
FR2825277B1 (en) * | 2001-05-30 | 2004-10-15 | Oreal | COSMETIC AND / OR DERMATOLOGICAL AND / OR PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ENZIME 3, B-HSD IHNIBITOR COMPOUND |
DE10151363A1 (en) * | 2001-10-17 | 2003-05-08 | Schering Ag | Use of estrogen receptor beta agonists to prepare medicaments for producing somatotropic and organotropic effects on the CNS, circulatory, skeletal and immune system in aging men and women |
AU2003206442A1 (en) * | 2002-02-21 | 2003-09-09 | Pantarhei Bioscience B.V. | Estrogenic component for treating decreased libido in women |
AU2003224561A1 (en) * | 2002-04-23 | 2003-11-10 | Sahltech I Goteborg Ab | Use of dhea for treatment of female hypopituitarism |
CA2496867A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
CA2574766A1 (en) * | 2004-06-23 | 2006-01-26 | Merck & Co., Inc. | Estrogen receptor modulators |
CA2584524C (en) | 2004-10-20 | 2012-02-07 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
AP2007003982A0 (en) * | 2004-11-01 | 2007-06-30 | Endorech Inc | Use of androgens to reduce the likelihood of acquring or to treat skin aging |
EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
EP2185112A4 (en) * | 2007-08-21 | 2012-01-18 | Harbor Biosciences Inc | Stabilized therapeutic compositions and formulations |
EP2053055A1 (en) * | 2007-10-24 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | 11.beta.-fluoro-3-acetoxyestra-3,5-diene-17-one and method for its manufacture |
JP2010109894A (en) * | 2008-10-31 | 2010-05-13 | Fujitsu Ltd | Acoustic wave filter, duplexer, communication module, and communication apparatus |
AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
WO2011156908A1 (en) | 2010-06-16 | 2011-12-22 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
US20130178747A1 (en) * | 2012-01-10 | 2013-07-11 | Peter J. Muran | Breast cancer precursor evaluation system and proactive breast wellness program |
CN105037532B (en) * | 2015-07-27 | 2018-02-09 | 苏州博源医疗科技有限公司 | 17 ketosteroid immunogenes, antibody and detection reagent and preparation method |
CN111830169B (en) * | 2020-07-24 | 2022-07-12 | 中山大学 | Compound for diagnosing polycystic ovarian syndrome and application thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US424954A (en) * | 1890-04-08 | Table-knife | ||
US279982A (en) * | 1883-06-26 | Thomas beid | ||
US816689A (en) * | 1904-07-07 | 1906-04-03 | Charles M Stevenson | Merry-go-round. |
CH203260A (en) | 1936-11-24 | 1939-02-28 | Dreiding Boris | Means for the local production of heat. |
US2185187A (en) * | 1938-05-23 | 1940-01-02 | Vlieg Gerard A De | Rotary cutter |
FR672M (en) * | 1960-08-31 | 1961-07-17 | ||
US3797444A (en) | 1971-04-19 | 1974-03-19 | H Stubbs | Towing guide |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
US4040401A (en) | 1974-11-05 | 1977-08-09 | Ethyl Corporation | Spark vacuum advance control |
US4064654A (en) | 1975-03-20 | 1977-12-27 | H. G. Olson & Co., Inc. | Sealed closures with weather stripping |
JPS53144014A (en) | 1977-05-20 | 1978-12-15 | Masaya Koyama | Automatic sprayer |
DE3333240A1 (en) | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS |
US4634694A (en) | 1984-01-14 | 1987-01-06 | Akzo N.V. | Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives |
US4725439A (en) | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US5155045A (en) * | 1985-01-25 | 1992-10-13 | Trustees Of The University Of Penn. | Use of male essence to alter female endocrine response |
US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US5887216A (en) * | 1997-03-19 | 1999-03-23 | Ricoh Company, Ltd. | Method and system to diagnos a business office device based on operating parameters set by a user |
US5686465A (en) * | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
KR900701242A (en) | 1988-12-01 | 1990-12-01 | 스타이너 브이. 캔스타드 | Transdermal delivery composition of estradiol |
US5461042A (en) * | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
EP0485392B1 (en) * | 1989-07-07 | 1998-09-09 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
US5116828A (en) | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
US5641768A (en) * | 1989-11-17 | 1997-06-24 | Loria; Roger M. | 5-androstene 3β, 17β diol for treatment |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5424463A (en) * | 1990-08-29 | 1995-06-13 | Humanetics Corporation | Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process |
US5183815A (en) * | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
US5206008A (en) * | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
AU676470B2 (en) * | 1992-02-24 | 1997-03-13 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
FR2696934B1 (en) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Derivatives of natural hydroxyl 3B steroids having properties of triggering and stimulating immunity, composition containing them and process for obtaining them. |
US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
ATE275957T1 (en) | 1993-01-19 | 2004-10-15 | Endorech Inc | THERAPEUTIC USES AND ADMINISTRATION SYSTEMS OF DEHYDROEPIANDROSTERONE |
US5387583A (en) * | 1993-04-20 | 1995-02-07 | Loria; Roger M. | Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof |
US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
ES2098193B1 (en) * | 1995-07-21 | 1997-12-01 | Gomez Jesus Calderon | NEW PHARMACEUTICAL FORMULATION OF DEHYDROEPIANDROSTERONE FOR TOPIC PERCUTANEOUS APPLICATION. |
US5828688A (en) * | 1995-10-26 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission |
US6653331B2 (en) * | 1996-07-03 | 2003-11-25 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
US6139873A (en) * | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
IT1292129B1 (en) * | 1997-06-11 | 1999-01-25 | Sunnimex Ltd | USEFUL MEDICATION FOR REDUCE FAT MASS AND INCREASE LEAN MASS IN WOMEN IN MENOPAUSE AND IN BOTH SEXES IN |
WO1999007381A1 (en) * | 1997-08-11 | 1999-02-18 | Weider Nutrition International, Inc. | Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
WO1999021562A1 (en) * | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
CN1879630A (en) * | 1998-06-11 | 2006-12-20 | 内部研究股份有限公司 | Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US6284262B1 (en) * | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
WO2001001969A2 (en) * | 1999-07-06 | 2001-01-11 | Endorecherche, Inc. | Methods of treating and/or suppressing weight gain |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
AU2002309919B2 (en) * | 2001-05-16 | 2008-04-10 | Barr Laboratories, Inc. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
-
1999
- 1999-06-10 CN CNA2006100840974A patent/CN1879630A/en active Pending
- 1999-06-10 ID IDW20010063A patent/ID27922A/en unknown
- 1999-06-10 NZ NZ536787A patent/NZ536787A/en unknown
- 1999-06-10 AU AU41274/99A patent/AU4127499A/en not_active Abandoned
- 1999-06-10 IL IL14022599A patent/IL140225A0/en unknown
- 1999-06-10 RU RU2001101492/15A patent/RU2221569C2/en not_active IP Right Cessation
- 1999-06-10 CN CNB998086371A patent/CN1243550C/en not_active Expired - Fee Related
- 1999-06-10 KR KR1020007014057A patent/KR100679735B1/en not_active IP Right Cessation
- 1999-06-10 AR ARP990102786A patent/AR018660A1/en unknown
- 1999-06-10 KR KR1020067016678A patent/KR20060098399A/en not_active Application Discontinuation
- 1999-06-10 TR TR2001/02867T patent/TR200102867T2/xx unknown
- 1999-06-10 WO PCT/CA1999/000537 patent/WO1999063973A2/en active IP Right Grant
- 1999-06-10 CN CNB2004100826380A patent/CN100377711C/en not_active Expired - Fee Related
- 1999-06-10 PL PL99345955A patent/PL345955A1/en not_active IP Right Cessation
- 1999-06-10 HU HU0102483A patent/HUP0102483A3/en unknown
- 1999-06-10 CA CA002334702A patent/CA2334702C/en not_active Expired - Fee Related
- 1999-06-10 KR KR1020067016679A patent/KR20060098400A/en not_active Application Discontinuation
- 1999-06-10 EP EP99924625A patent/EP1083904A2/en not_active Ceased
- 1999-06-10 JP JP2000553042A patent/JP2002517432A/en active Pending
- 1999-06-10 MX MXPA00012304A patent/MXPA00012304A/en not_active Application Discontinuation
- 1999-06-10 EP EP06018947A patent/EP1731157A3/en not_active Withdrawn
- 1999-06-10 BR BR9911115-2A patent/BR9911115A/en not_active Application Discontinuation
- 1999-06-10 TR TR2001/00063T patent/TR200100063T2/en unknown
- 1999-06-11 TW TW095106594A patent/TWI283579B/en not_active IP Right Cessation
- 1999-06-11 US US09/332,356 patent/US6432940B1/en not_active Expired - Fee Related
- 1999-06-11 TW TW088109823A patent/TWI263499B/en not_active IP Right Cessation
- 1999-06-11 MY MYPI99002408A patent/MY131522A/en unknown
-
2000
- 2000-12-08 ZA ZA200007299A patent/ZA200007299B/en unknown
- 2000-12-11 NO NO20006286A patent/NO20006286L/en not_active Application Discontinuation
-
2001
- 2001-11-21 HK HK01108194A patent/HK1037329A1/en not_active IP Right Cessation
- 2001-11-21 HK HK05109960A patent/HK1078004A1/en not_active IP Right Cessation
-
2002
- 2002-06-10 US US10/166,463 patent/US6964955B2/en not_active Expired - Fee Related
- 2002-06-10 US US10/166,428 patent/US20020187964A1/en not_active Abandoned
- 2002-06-10 US US10/166,423 patent/US20020187973A1/en not_active Abandoned
- 2002-06-10 US US10/170,083 patent/US20020187970A1/en not_active Abandoned
- 2002-06-10 US US10/167,729 patent/US20020187969A1/en not_active Abandoned
- 2002-06-10 US US10/166,506 patent/US20020187967A1/en not_active Abandoned
- 2002-06-10 US US10/167,727 patent/US20020187968A1/en not_active Abandoned
- 2002-06-10 US US10/166,505 patent/US20020187966A1/en not_active Abandoned
- 2002-06-10 US US10/166,424 patent/US6884795B2/en not_active Expired - Fee Related
- 2002-06-10 US US10/166,427 patent/US6995150B2/en not_active Expired - Fee Related
-
2006
- 2006-05-17 IL IL175723A patent/IL175723A0/en unknown
-
2007
- 2007-04-11 US US11/734,165 patent/US20080161277A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2334702A1 (en) | Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol | |
YATES et al. | Sex difference in rate of ring A reduction of Δ4-3-keto-steroids in vitro by rat liver | |
Santen et al. | Use of aromatase inhibitors in breast carcinoma. | |
YU54602A (en) | Drospirenone for hormone replacement therapy | |
HUT60139A (en) | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen | |
CA2467222A1 (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
ATE245992T1 (en) | PROGESTAGEN-FREE FORMULATIONS OF GNRH AND ESTROGEN FOR THE TREATMENT OF BENIGAN GYNECOLOGICAL DISORDERS | |
AU5513194A (en) | Combination therapy for treatment of estrogen sensitive diseases | |
CA2205897A1 (en) | Compositions and methods for contraception and for treatment of benign gynecological disorders | |
MY126960A (en) | Administration of non-oral androgenic steroids to women | |
Kloosterboer et al. | Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments | |
UA92348C2 (en) | 17b-HSD1 AND STS INHIBITORS | |
WO2001003687A2 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
AU2561195A (en) | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding | |
WO2005047303A3 (en) | NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | |
AP2001002054A0 (en) | Use of biogenic estrogen sulfamates for hormone replacement therapy. | |
CA2504697A1 (en) | Methods for treating migraine | |
AU723713B2 (en) | Steroid compounds having contraceptive and anti-osteoporosis activity | |
UA85203C2 (en) | 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | |
Ward et al. | Hydroxylation of steroids by the isolated rat adrenal | |
WO2002053137A3 (en) | Pharmaceutical composition for treatment of phimosis using topical corticosteroid | |
WO1999045886A3 (en) | New contraceptive kit for monotherapy | |
HK1009403A1 (en) | Tnf receptor and steroid hormone dhea in a combined therapy | |
US20050032758A1 (en) | Hormone replacement therapy and depression | |
Weidenfeld et al. | Inhibition of prostaglandin synthesis in brain of rat by dexamethasone: lack of effect of dexamethasone phosphate ester and various hormonal steroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |